Last close As at 05/08/2026
EUR3.53
▲ −0.06 (−1.67%)
Market capitalisation
EUR21m
Research: TMT
CLIQ Digital’s FY22 update showed strong year-on-year growth across all KPIs, as it continues to roll out its subscription-based bundled-content streaming services. The results were broadly in line with our expectations and CLIQ finished the year with a stronger-than-expected net cash position of €10m. Looking ahead, driven by continued investment into marketing and content, management expects FY23 revenue and EBITDA to exceed €345m and €50m, respectively, reflecting growth of at least 25% and 15%. We will update our numbers following the publication of the annual report, scheduled for 21 February.
CLIQ Digital |
FY22 update |
Media |
1 February 2023 |
Share price performance
Business description
Analysts
CLIQ Digital is a research client of Edison Investment Research Limited |
||||||||||||||||||||||||||||||||||||
CLIQ Digital’s FY22 update showed strong year-on-year growth across all KPIs, as it continues to roll out its subscription-based bundled-content streaming services. The results were broadly in line with our expectations and CLIQ finished the year with a stronger-than-expected net cash position of €10m. Looking ahead, driven by continued investment into marketing and content, management expects FY23 revenue and EBITDA to exceed €345m and €50m, respectively, reflecting growth of at least 25% and 15%. We will update our numbers following the publication of the annual report, scheduled for 21 February.
Year end |
Revenue (€m) |
EBITDA |
EPS* |
DPS |
P/E |
Yield |
12/20 |
107.0 |
15.9 |
1.16 |
0.46 |
25.3 |
1.6 |
12/21 |
150.0 |
27.2 |
2.71 |
1.10 |
10.8 |
3.7 |
12/22e |
276.1** |
43.5** |
4.17 |
1.69 |
7.0 |
5.8 |
12/23e |
307.5 |
51.0 |
4.95 |
2.01 |
5.9 |
6.8 |
Note: *EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. Note: *EPS are diluted. **Reported.
CLIQ’s results were broadly in line with our expectations, delivering revenue of €276m (Edison: €275m, FY21: €150m) and EBITDA of €43.5m (Edison: €43.5m, FY21: €27m). Operating free cash flow was slightly lower in the year, although ahead of our expectations, at €15m (Edison: €11.4m, FY21: €16m), as a result of the higher marketing expenditure and launch in December of the cliq.de platform, CLIQ’s relatively low-cost German subscription multi-entertainment portal. cliq.de is priced at €6.99 a month and includes a free 30-day trial period, which we believe should continue to drive an increase in sales and customer stickiness, helped by increased marketing spend.
CLIQ also reported some progress against stated KPIs: growing member numbers, the lifetime value of customer base and CLIQ’s profitability index. Paid memberships saw strong growth of 45% in the year, bringing the total number to 1.9m (FY21: 1.3m). The lifetime value of the customer base continued to grow, reaching €141m in the year (FY21: €87m), ahead of management’s expectation of €110m. The sustained high levels of investment in marketing in the period resulted in a fall in CLIQ’s profitability index (six month expected revenue per customer over cost of acquiring them) to 1.45x (FY21: 1.59x). Although below prior guidance of 1.51x, CLIQ notes the increased marketing expenditure was in order to recognise higher gross profit.
|
|
Research: Healthcare
Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical efforts towards exploring the applicability and efficacy of paxalisib in non-central nervous system (CNS) oncology indications such as melanoma and other solid tumors, including breast cancer. Post-period, Kazia announced a A$4.5m fund-raise through a two-stage private placement of 40.9m new shares (25.4m unconditional shares and 15.5m conditional shares) at A$0.11 per share. Management intends to use the proceeds to support its development programs (including the paxalisib GBM AGILE study due to readout in H2 CY23) and working capital requirements. The period-end net cash balance stood at A$4.4m and this, along with the A$4.5m fund-raise, should provide headroom into H2 CY23, based on current burn rates.